1. Home
  2. CLPS vs BOLD Comparison

CLPS vs BOLD Comparison

Compare CLPS & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CLPS Incorporation

CLPS

CLPS Incorporation

HOLD

Current Price

$0.92

Market Cap

24.7M

Sector

Technology

ML Signal

HOLD

Logo Boundless Bio Inc.

BOLD

Boundless Bio Inc.

HOLD

Current Price

$1.22

Market Cap

28.4M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
CLPS
BOLD
Founded
2005
2018
Country
Hong Kong
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
24.7M
28.4M
IPO Year
2018
2024

Fundamental Metrics

Financial Performance
Metric
CLPS
BOLD
Price
$0.92
$1.22
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$4.00
AVG Volume (30 Days)
22.4K
131.0K
Earning Date
03-04-2026
11-05-2025
Dividend Yield
13.54%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$164,481,414.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
15.17
N/A
52 Week Low
$0.80
$1.00
52 Week High
$1.88
$2.54

Technical Indicators

Market Signals
Indicator
CLPS
BOLD
Relative Strength Index (RSI) 59.07 46.13
Support Level $0.84 $1.19
Resistance Level $0.90 $1.31
Average True Range (ATR) 0.03 0.07
MACD 0.00 -0.00
Stochastic Oscillator 85.71 12.50

Price Performance

Historical Comparison
CLPS
BOLD

About CLPS CLPS Incorporation

CLPS Inc. is an IT consulting and solutions provider serving international clients in the banking, wealth management, e-commerce, and automotive sectors. The company drives digital transformation using AI, cloud computing, and big data, offering IT consulting, customized solutions, virtual banking training, recruitment, professional training, and software services. It operates mainly in two segments: IT services, which generate the majority of its revenue, and academic education services. The company has a presence in Hong Kong, Singapore, Mainland China, India, Malaysia, and Japan, with the majority of its revenue coming from Mainland China.

About BOLD Boundless Bio Inc.

Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.

Share on Social Networks: